<DOC>
	<DOC>NCT02531113</DOC>
	<brief_summary>The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.</brief_summary>
	<brief_title>Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description>This open-label trial is composed of two periods: Induction and Extension. All eligible patients will be enrolled into the 12-Week Induction period and receive study medication. Patients who complete the Induction period may then be eligible to enter the 100-Week Extension period where they will continue to receive study medication.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Crohn's disease (CD) confirmed by endoscopy and histology Active disease as evaluated by Crohn's Disease Activity Index Score and Simple Endoscopic Score for CD Inadequate response to aminosalicylates, corticosteroids, immunomodulators or biologic therapy Key Diagnosis of ulcerative colitis or indeterminate colitis Known strictures/stenosis leading to symptoms of obstruction Current stoma or need for ileostomy or colostomy Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk History of uveitis or known macular edema History of colonic dysplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>